--- title: "ANI Pharmaceuticals (ANIP) news: lawsuit" url: "https://aibio.space/companies/ani-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ANIP lawsuit news: ANI and Novitium face two generic drug patent suits and antitrust counterclaims in a third. ANI Pharmaceuticals, Inc." --- ANIP ANI Pharmaceuticals, Inc. NASDAQ · United States # ANI Pharmaceuticals (ANIP) news ANIP lawsuit news Legal · 2026-08-07 ## [ANI loses post-trial motions in CG Oncology royalty case and defends Acella suit](https://aibio.space/news/ani-loses-post-trial-motions-cg-oncology-royalty-case-defends-acella/) A Delaware court denied ANI's bid for a new trial against CG Oncology on July 16, and ANI plans to appeal. In Minnesota, ANI is defending Acella's Lanham Act suit, with summary judgment argument set for August 25. ## Latest ANI Pharmaceuticals news 1. 2026-08-07 Legal [ANI and Novitium face two generic drug patent suits and antitrust counterclaims in a third](https://aibio.space/news/ani-novitium-face-two-generic-drug-patent-suits-antitrust/) Orphalan sued Novitium, and Xeris and Strongbridge sued Novitium and ANI. In a Harmony patent case against AET and Sandoz entities, the defendants counterclaim against Harmony and Novitium. 2. 2025-09-26 Financings [ANI Pharmaceuticals forces conversion of last Series A preferred into 482,320 common shares](https://aibio.space/news/ani-pharmaceuticals-forces-conversion-last-series-preferred-482-320/) ANI mandatorily converted the last 20,000 preferred shares into 482,320 common shares on September 26, 2025. The filing reports no cash proceeds, and no preferred shares remain outstanding. ## ANI Pharmaceuticals at a glance - **Ticker**: ANIP - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $360.2 million ### Related companies - [Generate Biomedicines](https://aibio.space/companies/generate-biomedicines/) NASDAQ: GENB - [Stoke Therapeutics](https://aibio.space/companies/stoke-therapeutics/) NASDAQ: STOK - [Calithera Biosciences](https://aibio.space/companies/calithera-biosciences/) OTC: CALA - [Lakewood-Amedex Biotherapeutics](https://aibio.space/companies/lakewood-amedex-biotherapeutics/) NASDAQ: LABT - [Aspira Women's Health](https://aibio.space/companies/aspira-women-s-health/) OTC: AWHL - [Caris Life Sciences](https://aibio.space/companies/caris-life-sciences/) NASDAQ: CAI - [Neurogene](https://aibio.space/companies/neurogene/) NASDAQ: NGNE - [Cabaletta Bio](https://aibio.space/companies/cabaletta-bio/) NASDAQ: CABA ### Also on NASDAQ - [Unicycive Therapeutics](https://aibio.space/companies/unicycive-therapeutics/) UNCY - [Quantum Biopharma](https://aibio.space/companies/quantum-biopharma/) QNTM - [Climb Bio](https://aibio.space/companies/climb-bio/) CLYM - [BioCardia](https://aibio.space/companies/biocardia/) BCDA - [Pulmonx](https://aibio.space/companies/pulmonx/) LUNG - [10x Genomics](https://aibio.space/companies/10x-genomics/) TXG ## What ANI Pharmaceuticals does ANI Pharmaceuticals describes itself as a diversified biopharmaceutical company that develops, manufactures and commercializes therapeutics through its Rare Disease, Generics and Brands businesses. On September 16, 2024, it acquired Alimera Sciences, adding two products, ILUVIEN and YUTIQ. In March 2025 the FDA approved an expanded ILUVIEN label to include chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS), in addition to diabetic macular edema (DME). The company is marketing ILUVIEN for both indications in the U.S. In the second quarter of 2025 it moved its U.S. promotional efforts from YUTIQ to ILUVIEN. ILUVIEN was already approved for both indications outside the U.S., including in seventeen European countries. ANI owns and operates three pharmaceutical manufacturing facilities, two in Baudette, Minnesota and one in East Windsor, New Jersey, which can produce oral solid dose products, semi-solids, liquids, topicals, controlled substances and potent products. It ceased operations at a facility in Oakville, Ontario as of March 31, 2023. | Product or program | What it is | Stage | |---|---|---| | ILUVIEN | Eye product for diabetic macular edema and posterior segment uveitis | approved | | YUTIQ | Eye product added through the Alimera acquisition | | Summarised from the company's [10-K filed Feb 27, 2026](https://www.sec.gov/Archives/edgar/data/1023024/000102302426000014/anip-20251231.htm). ## ANI Pharmaceuticals annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$51.7 million](https://www.sec.gov/Archives/edgar/data/1023024/000102302426000014/) | [$44.6 million](https://www.sec.gov/Archives/edgar/data/1023024/000102302426000014/) | | Net income (loss) | [$78.3 million](https://www.sec.gov/Archives/edgar/data/1023024/000102302426000014/) | [-$18.5 million](https://www.sec.gov/Archives/edgar/data/1023024/000102302426000014/) | | Cash from operations | [$185.2 million](https://www.sec.gov/Archives/edgar/data/1023024/000102302426000014/) | [$64.0 million](https://www.sec.gov/Archives/edgar/data/1023024/000102302426000014/) | | Cash and equivalents | [$285.6 million](https://www.sec.gov/Archives/edgar/data/1023024/000102302426000069/) | [$144.9 million](https://www.sec.gov/Archives/edgar/data/1023024/000102302426000069/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $360.2 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about ANI Pharmaceuticals Is ANI Pharmaceuticals involved in a lawsuit? Our latest story on this, dated Aug 7, 2026: "ANI and Novitium face two generic drug patent suits and antitrust counterclaims in a third". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/ani-novitium-face-two-generic-drug-patent-suits-antitrust/). What is the ticker symbol of ANI Pharmaceuticals? ANI Pharmaceuticals, Inc. trades under the ticker ANIP on NASDAQ. Where is ANI Pharmaceuticals listed? ANI Pharmaceuticals, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:BSFA; LS:A1W15D; LSX:A1W15D. What is the SEC CIK of ANI Pharmaceuticals? The SEC Central Index Key (CIK) for ANI Pharmaceuticals, Inc. is 1023024. Its filings are on SEC EDGAR. How many shares does ANI Pharmaceuticals have outstanding? 24,422,240 shares as of 2013-02-28, per the cover page of its 10-K filed 2013-02-28. Which country or territory is ANI Pharmaceuticals listed under? Our directory records ANI Pharmaceuticals, Inc. under United States. What does ANI Pharmaceuticals do? Our directory classifies ANI Pharmaceuticals, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of ANI Pharmaceuticals? The ISIN recorded for ANI Pharmaceuticals, Inc. is US00182C1036. Does aibio.space cover ANI Pharmaceuticals? aibio.space lists ANI Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is ANI Pharmaceuticals incorporated? SEC records list its state or country of incorporation as DE. What does ANI Pharmaceuticals develop? ANI Pharmaceuticals describes itself as a diversified biopharmaceutical company that develops, manufactures and commercializes therapeutics through its Rare Disease, Generics and Brands businesses. On September 16, 2024, it acquired Alimera Sciences, adding two products, ILUVIEN and YUTIQ. What is ILUVIEN from ANI Pharmaceuticals? ILUVIEN: Eye product for diabetic macular edema and posterior segment uveitis Stage: approved. What is YUTIQ from ANI Pharmaceuticals? YUTIQ: Eye product added through the Alimera acquisition Is ANI Pharmaceuticals profitable? ANI Pharmaceuticals, Inc. reported net income of $78.3 million for the fiscal year ended Dec 31, 2025, and generated $185.2 million of cash from operations, per its annual report to the SEC. How much does ANI Pharmaceuticals spend on research and development? $51.7 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: ANI Pharmaceuticals Members talk about ANI Pharmaceuticals (ANIP). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at ANI Pharmaceuticals, newest first. Each line links the filing it comes from. 1. 2026-04-07 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1023024/000102302426000034/ani-20260401.htm) 2. 2025-09-26 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,3.03). [Source](https://www.sec.gov/Archives/edgar/data/1023024/000102302425000099/ani-20250926.htm) 3. 2025-05-23 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1023024/000102302425000056/ani-20250522.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ANIP on TradingView](https://www.tradingview.com/symbols/NASDAQ-ANIP/). ## SEC filings and registration - **SEC name**: Ani Pharmaceuticals Inc - **CIK**: 1023024 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: ANIP (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: 104 CARNEGIE CENTER DRIVE SUITE 300, PRINCETON, NJ, 08540 - **Phone**: 6097591810 - **Shares outstanding**: 24,422,240 as of 2013-02-28 (10-K filed 2013-02-28) - **Former names**: BIOSANTE PHARMACEUTICALS INC; BEN ABRAHAM TECHNOLOGIES INC ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1023024/000102302426000071/ani-20260819.htm) filed 2026-08-24 - [10-Q](https://www.sec.gov/Archives/edgar/data/1023024/000102302426000069/anip-20260630.htm) filed 2026-08-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1023024/000102302426000068/ani-20260807.htm) filed 2026-08-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1023024/000102302426000056/ani-20260521.htm) filed 2026-05-21 - [8-K](https://www.sec.gov/Archives/edgar/data/1023024/000102302426000054/ani-20260513.htm) filed 2026-05-13 - [10-Q](https://www.sec.gov/Archives/edgar/data/1023024/000102302426000050/anip-20260331.htm) filed 2026-05-08 - [8-K](https://www.sec.gov/Archives/edgar/data/1023024/000102302426000049/ani-20260508.htm) filed 2026-05-08 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1023024/000102302426000039/anip-20260408.htm) filed 2026-04-09 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001023024), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details ANI Pharmaceuticals, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ANIP, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: ANI Pharmaceuticals, Inc. - **Ticker**: ANIP - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US00182C1036 - **Other listed symbols**: GETTEX:BSFA; LS:A1W15D; LSX:A1W15D - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-ANIP/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/ani-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "ANI Pharmaceuticals (ANIP) news: lawsuit", 2026-10-31, https://aibio.space/companies/ani-pharmaceuticals/